Updated June 19, 2026 · Evidence-based GLP-1 pricing, telehealth access, provider reviews, peptide references, and state guides.Featured: NexLife transparent GLP-1 programs
Weight Loss · GLP-1
Semaglutide
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with a 7-day half-life, used for chronic weight management and type 2 diabetes. Sold under brand names Ozempic and Wegovy; widely compounded.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with a 7-day half-life, used for chronic weight management and type 2 diabetes. Sold under brand names Ozempic and Wegovy; widely compounded. Mechanism: GLP-1 receptor agonist. Typical route: Subcutaneous injection. FDA status: FDA-approved as Ozempic (2017, T2D) and Wegovy (2021, chronic weight management at BMI ≥30, or ≥27 with comorbidity). Compounded semaglutide is dispensed by pharmacy fulfillment subject to availability under valid prescr
Drug classGLP-1 receptor agonist
Half-life~7 days (weekly dosing)
RouteSubcutaneous injection
Typical maintenance2.4 mg/week
FDA statusApproved (Ozempic, Wegovy)
Compounded availabilityYes (503A/503B)
Mechanism of action
Semaglutide binds the GLP-1 receptor on pancreatic beta cells, stimulating glucose-dependent insulin release; on hypothalamic neurons, reducing appetite and slowing gastric emptying; and on cardiac tissue, contributing to its observed cardiovascular benefit.
Dosing reference
Standard titration: 0.25 mg/week (weeks 1-4), 0.5 mg/week (weeks 5-8), 1.0 mg/week (weeks 9-12), 1.7 mg/week (weeks 13-16), 2.4 mg/week (maintenance). Compounded formulations may follow the same schedule or use mg/mL concentrations of 2.5, 5, or 10 mg/mL.
Dosing information is provided for educational reference and is not medical advice. Patients must not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.
FDA status & regulatory framework
FDA-approved as Ozempic (2017, T2D) and Wegovy (2021, chronic weight management at BMI ≥30, or ≥27 with comorbidity). Compounded semaglutide is dispensed by pharmacy fulfillment subject to availability under valid prescription. The FDA published GLP-1 compounding guidance in April 2026.
Editor's Pick · #1 of 10
NexLife — Semaglutide Program
Editor's PickPhysician-led503A pharmacyAll 50 states
Physician-led telehealth platform with Dr. Adam Kennah as Medical Director. Compounded semaglutide from an FDA-registered 503A pharmacy, all-inclusive pricing covering medication, supplies, and prescriber visits.
Trade-offs to know: Compounded medication, not FDA-approved Wegovy or Ozempic. Cash-pay only — not billable to insurance. Async telehealth model (no live video by default).
Editor's Pick · #1 of 10
NexLife — Tirzepatide Program
Editor's PickPhysician-led503A pharmacyAll 50 states
Physician-led tirzepatide program with the same compounding pharmacy, prescriber team, and clinical protocols as the semaglutide program. Methylcobalamin combined formulations available.
Trade-offs to know: Compounded medication, not FDA-approved Zepbound or Mounjaro. Cash-pay only. Tirzepatide is a newer compound with a shorter real-world safety record than semaglutide.
U.S. telehealth providers that work with Semaglutide
Semaglutide is FDA-approved for type 2 diabetes (as Ozempic) and chronic weight management (as Wegovy). It is also widely compounded and prescribed off-label or as an alternative to brand-name versions through telehealth providers.
How much weight do people lose on semaglutide?
In the STEP-1 trial of Wegovy, participants lost an average of 14.9% of body weight at 68 weeks at the 2.4 mg/week maintenance dose. Real-world results vary; the average appears to be 10-15% at one year for adherent patients.
Who is the Editor's Pick for compounded semaglutide?
NexLife is the current Editor's Pick for compounded semaglutide, scoring 96/100 on the v3.0 six-pillar rubric — the highest in the category. NexLife dispenses through a 503A pharmacy with all 50 states covered.
SS
Lead Medical Researcher
Dr. Sam Saberian
Doctor of Pharmacy; leads protocol research, peptide pharmacology, and provider evaluation.
AS
Medical Reviewer
Alen A. Schwartz, MD
Board-certified physician; reviews clinical accuracy of every published page.
JE
Edited by
Julliana Edwards
Editorial standards, factual accuracy, and corrections workflow.
Clinical evidence and access data
This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.
Evidence point
Published data
What it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1
Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.
Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1
Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.
Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 status
FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.
Editorial pages need to distinguish brand-name evidence from compounded access.
State access
Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.
Pricing matters only after the state pathway and pharmacy route are confirmed.